Squarepoint
HTGM

Squarepoint’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Squarepoint’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,015
Closed -$71K – 3657
2021
Q2 		$71K Sell
1,015
-1,165
-53% -$63.1K ﹤0.01% 3069
2021
Q1 		$143K Buy
2,180
+47
+2% +$3.56K ﹤0.01% 2814
2020
Q4 		$123K Buy
+2,133
New +$124K ﹤0.01% 2674
2020
Q3 		– Sell
-70
Closed -$9K – 2963
2020
Q2 		$9K Sell
70
-459
-87% -$40.5K ﹤0.01% 2168
2020
Q1 		$31K Buy
+529
New +$51.8K ﹤0.01% 1758

Other funds holding HTGM

CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint's HTGM Position: Q3 2021 in Review

Squarepoint sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2021, closing a stake of 1,015 shares — an estimated $71K sold.

Squarepoint first reported a position in HTGM in Q1 2020 and held it in 5 quarters. The position peaked at $143K in Q1 2021. 23 funds tracked by Wall St. Rank hold HTGM as of Q3 2021.

  • Squarepoint reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 1,015 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2021, an estimated $71K.
  • Squarepoint first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
  • Squarepoint's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $143K in Q1 2021.
  • 23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.